Kayne Anderson Rudnick Investment Management LLC Has $195.56 Million Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Kayne Anderson Rudnick Investment Management LLC lifted its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 6.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 593,692 shares of the medical instruments supplier’s stock after acquiring an additional 37,702 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC’s holdings in West Pharmaceutical Services were worth $195,556,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of WST. Fidelis Capital Partners LLC bought a new stake in West Pharmaceutical Services during the 1st quarter worth approximately $27,000. Crewe Advisors LLC lifted its holdings in shares of West Pharmaceutical Services by 322.7% during the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 71 shares during the period. Quarry LP grew its stake in shares of West Pharmaceutical Services by 155.3% in the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock worth $34,000 after purchasing an additional 59 shares during the last quarter. Hazlett Burt & Watson Inc. acquired a new stake in West Pharmaceutical Services in the first quarter valued at $40,000. Finally, Northwest Investment Counselors LLC bought a new position in West Pharmaceutical Services during the 1st quarter worth $40,000. Institutional investors own 93.90% of the company’s stock.

Insider Transactions at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the sale, the vice president now directly owns 1,478 shares in the company, valued at approximately $443,400. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.53% of the stock is currently owned by corporate insiders.

West Pharmaceutical Services Stock Down 1.0 %

Shares of WST opened at $308.15 on Friday. The company has a market capitalization of $22.45 billion, a PE ratio of 40.65, a PEG ratio of 10.58 and a beta of 1.01. The stock’s 50-day moving average price is $303.37 and its two-hundred day moving average price is $337.42. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The company had revenue of $702.10 million during the quarter, compared to the consensus estimate of $729.36 million. During the same quarter in the previous year, the company earned $2.11 earnings per share. The business’s revenue was down 6.9% on a year-over-year basis. On average, analysts anticipate that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.